IFITM1 and metastatic neoplasm: In addition to these 18 genes under active investigation as drug targets two other highly expressed genes—CD97 [61], and IFITM1 [62]—have been proposed but not actively pursued as therapeutic antibody targets for primary or metastatic tumors.